Co-Author
This page shows the publications co-authored by Toni Choueiri and Guru Sonpavde.
Connection Strength
9.854
-
Incomplete Cross-Resistance Between Taxanes for Advanced Urothelial Carcinoma: Implications for Clinical Practice and Trial Design. Clin Genitourin Cancer. 2015 Jun; 13(3):250-6.
Score: 0.596
-
Precision medicine for metastatic renal cell carcinoma. Urol Oncol. 2014 Jan; 32(1):5-15.
Score: 0.557
-
Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol. 2013 Jul; 87(1):80-9.
Score: 0.526
-
Biomarkers: the next therapeutic hurdle in metastatic renal cell carcinoma. Br J Cancer. 2012 Sep 25; 107(7):1009-16.
Score: 0.513
-
The double edged sword of bleeding and clotting from VEGF inhibition in renal cancer patients. Curr Oncol Rep. 2012 Aug; 14(4):295-306.
Score: 0.509
-
CDH1 germline variants are enriched in patients with colorectal cancer, gastric cancer, and breast cancer. Br J Cancer. 2022 03; 126(5):797-803.
Score: 0.244
-
FGFR2/3 genomic alterations and response to Enfortumab Vedotin in metastatic urothelial carcinoma. BJUI Compass. 2022 Mar; 3(2):169-172.
Score: 0.242
-
Trans-ethnic variation in germline variants of patients with renal cell carcinoma. Cell Rep. 2021 03 30; 34(13):108926.
Score: 0.232
-
Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies. Cancer. 2021 03 15; 127(6):840-849.
Score: 0.226
-
Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors. J Urol. 2020 12; 204(6):1173-1179.
Score: 0.220
-
Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors. Cancer Immunol Res. 2020 08; 8(8):1075-1084.
Score: 0.218
-
Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors. J Immunother Cancer. 2020 03; 8(1).
Score: 0.215
-
Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinoma. Genet Med. 2020 04; 22(4):709-718.
Score: 0.212
-
An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma. Oncologist. 2019 02; 24(2):202-210.
Score: 0.194
-
Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2). Br J Cancer. 2018 05; 118(11):1434-1441.
Score: 0.190
-
Enrichment of FGFR3-TACC3 Fusions in Patients With Bladder Cancer Who Are Young, Asian, or Have Never Smoked. JCO Precis Oncol. 2018; 2.
Score: 0.190
-
Nomogram to Assess the Survival Benefit of New Salvage Agents for Metastatic Urothelial Carcinoma in the Era of Immunotherapy. Clin Genitourin Cancer. 2018 08; 16(4):e961-e967.
Score: 0.189
-
JAVELIN: avelumab another spear to fight urothelial carcinoma. Lancet Oncol. 2018 01; 19(1):5-7.
Score: 0.184
-
Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma. Eur Urol. 2017 10; 72(4):557-564.
Score: 0.176
-
Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. Cancer Immunol Res. 2017 04; 5(4):312-318.
Score: 0.175
-
Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial Carcinoma. Clin Genitourin Cancer. 2016 12; 14(6):494-498.
Score: 0.165
-
High Throughput Kinomic Profiling of Human Clear Cell Renal Cell Carcinoma Identifies Kinase Activity Dependent Molecular Subtypes. PLoS One. 2015; 10(9):e0139267.
Score: 0.158
-
Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial Carcinoma. J Urol. 2016 Feb; 195(2):277-82.
Score: 0.157
-
Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma. Eur Urol. 2016 Apr; 69(4):634-641.
Score: 0.157
-
Fatigue with vascular endothelial growth factor receptor tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors in patients with renal cell carcinoma (RCC) and other malignancies: A meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol. 2015 Aug; 95(2):251-63.
Score: 0.153
-
Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Crit Rev Oncol Hematol. 2015 May; 94(2):228-37.
Score: 0.150
-
Future directions and targeted therapies in bladder cancer. Hematol Oncol Clin North Am. 2015 Apr; 29(2):361-76, x.
Score: 0.150
-
Pancreatitis with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Crit Rev Oncol Hematol. 2015 Apr; 94(1):136-45.
Score: 0.150
-
Hepatotoxicity with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol. 2015 Mar; 93(3):257-76.
Score: 0.150
-
QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Br J Cancer. 2015 Jan 20; 112(2):296-305.
Score: 0.149
-
Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinoma. Clin Genitourin Cancer. 2015 Apr; 13(2):185-92.
Score: 0.148
-
Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma. Clin Genitourin Cancer. 2014 Dec; 12(6):395-8.
Score: 0.145
-
Impact of the number of prior lines of therapy and prior perioperative chemotherapy in patients receiving salvage therapy for advanced urothelial carcinoma: implications for trial design. Clin Genitourin Cancer. 2015 Feb; 13(1):71-9.
Score: 0.145
-
A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma. BJU Int. 2014 May; 113(5b):E137-43.
Score: 0.144
-
Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma. Clin Genitourin Cancer. 2014 Apr; 12(2):130-7.
Score: 0.138
-
Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design. Clin Genitourin Cancer. 2013 Dec; 11(4):495-500.
Score: 0.135
-
Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors. Br J Cancer. 2013 Jun 25; 108(12):2478-84.
Score: 0.135
-
Incidence and risk of treatment-related mortality in cancer patients treated with the mammalian target of rapamycin inhibitors. Ann Oncol. 2013 Aug; 24(8):2092-7.
Score: 0.134
-
Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. Eur Urol. 2013 Apr; 63(4):717-23.
Score: 0.130
-
Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J Clin Oncol. 2012 Feb 10; 30(5):507-12.
Score: 0.122
-
Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy? Eur Urol. 2012 Feb; 61(2):307-16.
Score: 0.121
-
Recent advances in immunotherapy for the treatment of prostate cancer. Expert Opin Biol Ther. 2011 Aug; 11(8):997-1009.
Score: 0.118
-
Towards a Better Understanding of Antibody-Drug Conjugates in Urothelial Carcinoma. Eur Urol Oncol. 2022 Jan 29.
Score: 0.061
-
Immune-related adverse events and kidney function decline in patients with genitourinary cancers treated with immune checkpoint inhibitors. Eur J Cancer. 2021 11; 157:50-58.
Score: 0.060
-
CDKN2A Alterations and Response to Immunotherapy in Solid Tumors. Clin Cancer Res. 2021 07 15; 27(14):4025-4035.
Score: 0.059
-
Author Correction: Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes. Nat Med. 2020 Oct; 26(10):1663.
Score: 0.056
-
Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes. Nat Med. 2020 07; 26(7):1041-1043.
Score: 0.055
-
A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma. Br J Cancer. 2020 02; 122(4):555-563.
Score: 0.053
-
Impact of tumor, treatment, and access on outcomes in bladder cancer: Can equal access overcome race-based differences in survival? Cancer. 2019 04 15; 125(8):1319-1329.
Score: 0.050
-
Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites. Clin Cancer Res. 2019 04 15; 25(8):2458-2470.
Score: 0.050
-
Sequential Response to FGFR3 Inhibition With Subsequent Exceptional Response to Atezolizumab in a Patient With FGFR3-TACC3 Fusion-Positive Metastatic Urothelial Carcinoma. JCO Precis Oncol. 2018; 2.
Score: 0.048
-
Characterizing trends in treatment modalities for localized muscle-invasive bladder cancer in the pre-immunotherapy era. World J Urol. 2018 Nov; 36(11):1767-1774.
Score: 0.048
-
The effect of treatment at minority-serving hospitals on outcomes for bladder cancer. Urol Oncol. 2018 05; 36(5):238.e7-238.e17.
Score: 0.047
-
Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 06; 15(6):804-834.
Score: 0.045
-
Incidence of Severe Nephrotoxicity With Cisplatin Based on Renal Function Eligibility Criteria: Indirect Comparison Meta-analysis. Am J Clin Oncol. 2016 10; 39(5):497-506.
Score: 0.043
-
Association of tumour microRNA profiling with outcomes in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy. Br J Cancer. 2016 06 28; 115(1):12-9.
Score: 0.042
-
Ruffling the Immunotherapy Response Paradigm with a Novel Personalized Peptide Vaccine. Eur Urol. 2016 07; 70(1):42-44.
Score: 0.041
-
Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis. Target Oncol. 2014 Sep; 9(3):195-204.
Score: 0.034
-
Metabolic complications with the use of mTOR inhibitors for cancer therapy. Cancer Treat Rev. 2014 Feb; 40(1):190-6.
Score: 0.034
-
Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis. J Clin Oncol. 2012 Dec 10; 30(35):4416-26.
Score: 0.032
-
Arterial thromboembolism in cancer patients treated with cisplatin: a systematic review and meta-analysis. J Natl Cancer Inst. 2012 Dec 05; 104(23):1837-40.
Score: 0.032
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.